Latest Ratios: P/E Ratio -0.5x · EV/EBITDA N/A · ROE -61.5%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $71M | $75M | $797M | $1.1B | $812M | $484M | $808M | — | — | — |
| Enterprise Value | $55M | $59M | $786M | $1.0B | $794M | $439M | $757M | — | — | — |
| P/E Ratio → | -0.47 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 673.04 | 83.86 | 63.91 | 19.32 | — | — | — |
| P/B Ratio | 0.39 | 0.41 | 2.62 | 2.25 | 2.59 | 2.43 | 2.85 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 640.22 | 82.01 | 58.04 | 18.10 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | — | — | — | -11654.7% | -1313.4% | -1288.1% | -99.6% | -2.2% | — | — |
| Net Profit Margin | — | — | — | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -61.5% | -61.5% | -54.1% | -41.0% | -48.1% | -40.3% | -29.4% | — | -2458.5% | -616.5% |
| ROA | -48.0% | -48.0% | -46.3% | -37.4% | -43.1% | -37.6% | -20.0% | -0.7% | -82.9% | -314.7% |
| ROIC | -49.2% | -49.2% | -47.9% | -38.5% | -42.4% | -37.8% | -42.7% | — | — | — |
| ROCE | -52.4% | -52.4% | -53.9% | -45.4% | -47.9% | -39.9% | -21.1% | -1.4% | -95.4% | -545.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.20 | 0.02 | 0.05 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.04 | -0.11 | -0.06 | -0.22 | -0.18 | — | — | -1.27 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -58.65 | -58.65 | -68.54 | -126.34 | -154.91 | — | -113.78 | -5.70 | — | — |
Net cash position: cash ($45M) exceeds total debt ($29M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.00 | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 | 12.14 | 1.48 |
| Quick Ratio | 12.00 | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 | 12.14 | 1.48 |
| Cash Ratio | 11.67 | 11.67 | 10.71 | 17.33 | 13.85 | 11.92 | 23.87 | 12.58 | 11.99 | 1.33 |
| Asset Turnover | — | — | — | 0.00 | 0.03 | 0.03 | 0.14 | 0.48 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 692.34 | 118.49 | 118.87 | 81.72 | 47.25 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $61M | $61M | $59M | $42M | $36M | $36M | $36M | $17M | $803497 |
Imminent capital dilution risk
According to recent market data, PLRX trades at a price-to-book ratio of 0.38, which, when compared to the broader biotechnology sector, suggests that investors are heavily discounting the company's intellectual property and future clinical potential due to the persistent absence of commercial revenue and significant cash burn.
The depressed P/B multiple indicates that the market is assigning little value to the company's asset base, likely reflecting skepticism regarding the probability of success for bexotegrast. This valuation level suggests that the market is pricing in a high likelihood of substantial equity dilution as the company approaches critical funding milestones.
As reported in financial statements, the company's ROIC has trended downward from -8.0% in 2023Q4 to -9.7% in 2026Q1, illustrating a consistent decay in the efficiency with which invested capital is deployed to advance the clinical pipeline toward regulatory approval.
The persistent negative returns on capital are a direct consequence of high R&D intensity without the offsetting benefit of commercialized products. This trend warrants close monitoring, as it suggests that the company's current development strategy is consuming capital at a rate that outpaces the incremental value created by clinical progress.
Based on the provided quarterly data, the current ratio has contracted from 17.72 in 2023Q4 to 16.89 in 2026Q1, which, while numerically high, masks the reality that the absolute cash position is rapidly depleting to levels that may soon threaten operational continuity.
While the current ratio appears robust, it is a misleading metric for a pre-revenue biotech where liquidity is entirely dependent on cash reserves rather than working capital cycles. Investors should interpret this liquidity position as highly vulnerable, given the lack of recurring inflows to support the ongoing, capital-intensive Phase 3 clinical trial requirements.
As observed in the financial data, the current ratio is the most commonly misapplied metric for PLRX, as it fails to account for the non-discretionary, high-burn nature of clinical-stage R&D expenditures that render traditional liquidity assessments largely irrelevant for this business model.
Relying on the current ratio obscures the true risk of insolvency, as it treats all current assets as equally available for operations, ignoring the fact that the company's primary 'asset' is clinical data rather than liquid capital. A more appropriate metric would be the 'cash runway' measured in months, which provides a clearer view of the timeline until the next necessary capital raise.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PLRX stock.
Pliant Therapeutics, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Pliant Therapeutics, Inc.'s return on equity (ROE) is -61.5%. The historical average is -45.8%.
Based on historical data, Pliant Therapeutics, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.